These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 30959763)

  • 1. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.
    Pusceddu S; Ghidini M; Torchio M; Corti F; Tomasello G; Niger M; Prinzi N; Nichetti F; Coinu A; Di Bartolomeo M; Cabiddu M; Passalacqua R; de Braud F; Petrelli F
    Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30959763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.
    Nichetti F; Rota S; Ambrosini P; Pircher C; Gusmaroli E; Droz Dit Busset M; Pusceddu S; Sposito C; Coppa J; Morano F; Pietrantonio F; Di Bartolomeo M; Mariani L; Mazzaferro V; de Braud F; Niger M
    JAMA Netw Open; 2024 Jan; 7(1):e2350756. PubMed ID: 38190183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer.
    Chen J; Hua Q; Wang H; Zhang D; Zhao L; Yu D; Pi G; Zhang T; Lin Z
    BMC Cancer; 2021 Jul; 21(1):853. PubMed ID: 34301232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
    Arciero V; Luo J; Parmar A; Dai WF; Beca JM; Raphael MJ; Isaranuwatchai W; Habbous S; Tadrous M; Earle CC; Biagi JJ; Mittmann N; Arias J; Gavura S; Chan KKW
    JNCI Cancer Spectr; 2022 Jul; 6(4):. PubMed ID: 35758620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis.
    Schlick K; Gantschnigg A; Seymer A; Huemer F; Greil R; Weiss L
    Cancer Med; 2023 Aug; 12(16):16997-17004. PubMed ID: 37537780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Stainthorpe A; Greenhalgh J; Bagust A; Richardson M; Boland A; Beale S; Duarte R; Kotas E; Banks L; Palmer D
    Pharmacoeconomics; 2018 Oct; 36(10):1153-1163. PubMed ID: 29600384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
    Klein-Brill A; Amar-Farkash S; Lawrence G; Collisson EA; Aran D
    JAMA Netw Open; 2022 Jun; 5(6):e2216199. PubMed ID: 35675073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma.
    Baron MK; Wang X; Nevala-Plagemann C; Moser JC; Haaland B; Garrido-Laguna I
    Pancreas; 2021 Jul; 50(6):796-802. PubMed ID: 34347727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine
    Chiorean EG; Cheung WY; Giordano G; Kim G; Al-Batran SE
    Ther Adv Med Oncol; 2019; 11():1758835919850367. PubMed ID: 31205510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer.
    Gharaibeh M; McBride A; Bootman JL; Patel H; Abraham I
    J Med Econ; 2017 Apr; 20(4):345-352. PubMed ID: 27919186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study.
    Queck A; Elango S; Koch C; Walter D; Schmidt J; Trebicka J; Trojan J; Pession U; Finkelmeier F; Waidmann O
    Oncol Res Treat; 2022; 45(3):79-87. PubMed ID: 34875671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Safety and Efficacy of Therapeutic Options in Resectable and Advanced/Metastatic Pancreatic Cancer: A Systematic Review and Indirect Comparison.
    Kharat A; Brendle M; Chhibber A; Chaiyakunapruk N; Biskupiak J
    Oncol Res Treat; 2021; 44(9):476-484. PubMed ID: 34315166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer.
    Kurimoto M; Kimura M; Usami E; Iwai M; Hirose T; Kawachi S; Yoshimura T
    Mol Clin Oncol; 2017 Jul; 7(1):125-130. PubMed ID: 28685089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study.
    Zaibet S; Hautefeuille V; Auclin E; Lièvre A; Tougeron D; Sarabi M; Gilabert M; Wasselin J; Edeline J; Artru P; Bechade D; Morin C; Ducoulombier A; Taieb J; Pernot S
    Br J Cancer; 2022 Jun; 126(10):1394-1400. PubMed ID: 35094032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis.
    Chae H; Jeong H; Cheon J; Chon HJ; Ryu H; Kim IH; Kang MJ; Jeong JH; Ryoo BY; Kim KP; Yoo C
    Ther Adv Med Oncol; 2020; 12():1758835920923424. PubMed ID: 32523632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness and resource utilization of
    Braiteh F; Patel MB; Parisi M; Ni Q; Park S; Faria C
    Cancer Manag Res; 2017; 9():141-148. PubMed ID: 28461766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine.
    Di Costanzo F; Di Costanzo F; Antonuzzo L; Mazza E; Giommoni E
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial.
    Assenat E; de la Fouchardière C; Portales F; Ychou M; Debourdeau A; Desseigne F; Iltache S; Fiess C; Mollevi C; Mazard T
    ESMO Open; 2021 Dec; 6(6):100318. PubMed ID: 34837745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
    Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
    JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.